These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

171 related articles for article (PubMed ID: 25182712)

  • 1. Distribution and antimicrobial susceptibility profile of extended-spectrum β-lactamase-producing Proteus mirabilis strains recently isolated in Japan.
    Kanayama A; Kobayashi I; Shibuya K
    Int J Antimicrob Agents; 2015 Feb; 45(2):113-8. PubMed ID: 25182712
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Rapidly spreading CTX-M-type beta-lactamase-producing Proteus mirabilis in Japan.
    Kanayama A; Iyoda T; Matsuzaki K; Saika T; Ikeda F; Ishii Y; Yamaguchi K; Kobayashi I
    Int J Antimicrob Agents; 2010 Oct; 36(4):340-2. PubMed ID: 20609568
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Antimicrobial susceptibilities of Proteus mirabilis: a longitudinal nationwide study from the Taiwan surveillance of antimicrobial resistance (TSAR) program.
    Wang JT; Chen PC; Chang SC; Shiau YR; Wang HY; Lai JF; Huang IW; Tan MC; Lauderdale TL;
    BMC Infect Dis; 2014 Sep; 14():486. PubMed ID: 25192738
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Regional Spread of CTX-M-2-Producing Proteus mirabilis with the Identical Genetic Structure in Japan.
    Kato K; Matsumura Y; Yamamoto M; Nagao M; Takakura S; Ichiyama S
    Microb Drug Resist; 2017 Jul; 23(5):590-595. PubMed ID: 27834610
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Regional outbreak of CTX-M-2 β-lactamase-producing Proteus mirabilis in Japan.
    Nakano R; Nakano A; Abe M; Inoue M; Okamoto R
    J Med Microbiol; 2012 Dec; 61(Pt 12):1727-1735. PubMed ID: 22935848
    [TBL] [Abstract][Full Text] [Related]  

  • 6. CTX-M-1 extended-spectrum beta-lactamase-producing Proteus mirabilis in Greece.
    Karapavlidou P; Sofianou D; Manolis EN; Pournaras S; Tsakris A
    Microb Drug Resist; 2005; 11(4):351-4. PubMed ID: 16359194
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Occurrence and molecular analysis of extended-spectrum {beta}-lactamase-producing Proteus mirabilis in Hong Kong, 1999-2002.
    Ho PL; Ho AY; Chow KH; Wong RC; Duan RS; Ho WL; Mak GC; Tsang KW; Yam WC; Yuen KY
    J Antimicrob Chemother; 2005 Jun; 55(6):840-5. PubMed ID: 15857942
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Extended-spectrum β-lactamase (ESBL) in Danish clinical isolates of Escherichia coli and Klebsiella pneumoniae: prevalence, β-lactamase distribution, phylogroups, and co-resistance.
    Hansen DS; Schumacher H; Hansen F; Stegger M; Hertz FB; Schønning K; Justesen US; Frimodt-Møller N;
    Scand J Infect Dis; 2012 Mar; 44(3):174-81. PubMed ID: 22364227
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Spread of multidrug-resistant Proteus mirabilis isolates producing an AmpC-type beta-lactamase: epidemiology and clinical management.
    Luzzaro F; Brigante G; D'Andrea MM; Pini B; Giani T; Mantengoli E; Rossolini GM; Toniolo A
    Int J Antimicrob Agents; 2009 Apr; 33(4):328-33. PubMed ID: 19095415
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Prevalence and resistance patterns of extended-spectrum and AmpC β-lactamase in Escherichia coli, Klebsiella pneumoniae, Proteus mirabilis, and Salmonella serovar Stanley in a Korean tertiary hospital.
    Park SD; Uh Y; Lee G; Lim K; Kim JB; Jeong SH
    APMIS; 2010 Oct; 118(10):801-8. PubMed ID: 20854475
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Dissemination of Proteus mirabilis isolates harboring CTX-M-14 and CTX-M-3 beta-lactamases at 2 hospitals in Taiwan.
    Wu LT; Wu HJ; Chung JG; Chuang YC; Cheng KC; Yu WL
    Diagn Microbiol Infect Dis; 2006 Feb; 54(2):89-94. PubMed ID: 16406185
    [TBL] [Abstract][Full Text] [Related]  

  • 12. A binational cohort study of intestinal colonization with extended-spectrum β-lactamase-producing Proteus mirabilis in patients admitted to rehabilitation centres.
    Adler A; Baraniak A; Izdebski R; Fiett J; Gniadkowski M; Hryniewicz W; Salvia A; Rossini A; Goossens H; Malhotra S; Lerman Y; Elenbogen M; Carmeli Y;
    Clin Microbiol Infect; 2013 Feb; 19(2):E51-8. PubMed ID: 23210906
    [TBL] [Abstract][Full Text] [Related]  

  • 13. [Characteristic of fluoroquinolone resistant clinical isolates of K. pneumoniae, P. mirabilis and E. coli producing ESBL and AmpC beta-lactamases].
    Rzeczkowska M; Piekarska K; Gierczyński R
    Med Dosw Mikrobiol; 2012; 64(4):285-95. PubMed ID: 23484420
    [TBL] [Abstract][Full Text] [Related]  

  • 14. The first detection of CTX-M-14 extended-spectrum beta-lactamase among diverse beta-lactamase-producing Proteus mirabilis clinical isolates.
    Yong D; Lim YS; Roh KH; Choi YS; Park DY; Yum JH; Kim JM; Lee K; Chong Y
    Diagn Microbiol Infect Dis; 2006 Mar; 54(3):237-9. PubMed ID: 16427241
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Expansion and countrywide dissemination of ST11, ST15 and ST147 ciprofloxacin-resistant CTX-M-15-type beta-lactamase-producing Klebsiella pneumoniae epidemic clones in Hungary in 2005--the new 'MRSAs'?
    Damjanova I; Tóth A; Pászti J; Hajbel-Vékony G; Jakab M; Berta J; Milch H; Füzi M
    J Antimicrob Chemother; 2008 Nov; 62(5):978-85. PubMed ID: 18667450
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Prevalence of extended-spectrum beta-lactamases in Proteus mirabilis in a Taiwanese university hospital, 1999 to 2005: identification of a novel CTX-M enzyme (CTX-M-66).
    Wu JJ; Chen HM; Ko WC; Wu HM; Tsai SH; Yan JJ
    Diagn Microbiol Infect Dis; 2008 Feb; 60(2):169-75. PubMed ID: 17913434
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Characteristics of bacteremia caused by extended-spectrum beta-lactamase-producing Proteus mirabilis.
    Kurihara Y; Hitomi S; Oishi T; Kondo T; Ebihara T; Funayama Y; Kawakami Y
    J Infect Chemother; 2013 Oct; 19(5):799-805. PubMed ID: 23371453
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Increase in beta-lactam-resistant Proteus mirabilis strains due to CTX-M- and CMY-type as well as new VEB- and inhibitor-resistant TEM-type beta-lactamases.
    Aragón LM; Mirelis B; Miró E; Mata C; Gómez L; Rivera A; Coll P; Navarro F
    J Antimicrob Chemother; 2008 May; 61(5):1029-32. PubMed ID: 18292096
    [TBL] [Abstract][Full Text] [Related]  

  • 19. [Detection of bla(CTX-M) beta-lactamase genes in extended-spectrum beta-lactamase producing gram-negative bacteria].
    Bayraktar B; Toksoy B; Bulut E
    Mikrobiyol Bul; 2010 Apr; 44(2):187-96. PubMed ID: 20549952
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Antimicrobial Susceptibility and Molecular Epidemiology of
    Lin MF; Liou ML; Kuo CH; Lin YY; Chen JY; Kuo HY
    Microb Drug Resist; 2019 Nov; 25(9):1338-1346. PubMed ID: 31295061
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.